The prescription blood-thinners Pradaxa (dabigatran) and warfarin aim to reduce stroke and other cardiovascular disorders, but like most medications, they do carry some risks.

Blood thinner dabigatran ( Pradaxa ), approved in 2010 to prevent stroke in patients with atrial fibrillation, a common heart arrhythmia, is linked to an increased risk of heart attack, a new trial suggests.